Inhibition of tumor angiogenesis is an interesting strategy in cancer management, which relevance has been further denoted by the approval of VEGF-inhibitor bevacizumab for colorectal cancer (Hanahan and Weinberg, 2011). The gene discussed is VEGFA; the disease is colorectal cancer.